Ethinylestradiol/levonorgestrel - Barr Pharmaceuticals/Duramed Pharmaceuticals

Drug Profile

Ethinylestradiol/levonorgestrel - Barr Pharmaceuticals/Duramed Pharmaceuticals

Alternative Names: DP3; DR-103; DR-105; Lo Seasonique; Seasonique

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Duramed Pharmaceuticals Inc
  • Developer Duramed Pharmaceuticals Inc; Teva Pharmaceutical Industries
  • Class Alkylated estrogenic steroids; Contraceptives; Hormonal replacements; Norpregnanes; Norpregnatrienes; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy
  • Discontinued Menstrual migraine

Most Recent Events

  • 04 Jul 2014 Preregistration for Contraception/Pregnancy (Prevention) in European Union (PO)
  • 04 Jul 2014 The EMA's Committee for Medicinal Products for Human Use recommends approval of Seasonique® for Contraception/Pregnancy (Prevention) in European Union
  • 14 Apr 2014 Registered for Contraception/Pregnancy (Prevention) in Brazil (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top